RxDoctor Payments Data

Julia Parkhurst, PA

Physician Assistant · Charlotte, NCNPI 1427267509

Payments from drug & device makers

$9,018in general payments, 2019–2025

Across 348 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$2K
  • AstraZeneca$2K
  • GSK$1K
  • Pfizer$611
  • Novartis$589
  • Kaleo, Inc.$552
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$1341%
  • Food & beverage$8,59295%
  • Education$2923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,018 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$13,094
Medicare patients
89
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko12$50,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$16,435
Breo ElliptaFluticasone/Vilanterol19$11,606
Azelastine Hcl42$1,128
Olopatadine Hcl11$910
Ipratropium Bromide21$786
Albuterol Sulfate HfaAlbuterol Sulfate25$739
Montelukast Sodium41$666
Fluticasone Propionate32$631
Prednisone22$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire$1,553$50,18412 claims
GSKTrelegy Ellipta, Breo Ellipta$1,468$28,04148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →